The 35th annual Alton Ochsner Award Relating Smoking and Disease has been awarded to Paul J. Kenny, PhD, Ward-Coleman professor and chair, Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai in New York.
This honor bestowed by Ochsner Health recognizes scientists who have made major contributions regarding the relationship between smoking and disease, along with the development of innovative treatment modalities. The award is named in honor of Alton Ochsner, MD, co-founder of the Ochsner Clinic (now known as Ochsner Health) based in New Orleans. In 1939, Dr. Ochsner published the first evidence indicating that tobacco smoking was the major cause of lung cancer. As the 2020 honoree, Kenny will receive a $15,000 honorarium, an award medallion, and a plaque describing key research findings.
“Research is at the core of all our Centers of Excellence. At Ochsner, we have a rich legacy of recognizing and supporting research critical to progressing our understanding of complex healthcare issues – including the work begun by Dr. Alton Ochsner back in 1939 relating smoking and lung cancer. As our 2020 honoree, Dr. Kenny joins the ranks of other research giants in this field for his contributions studying nicotine addition,” said Leonardo Seoane, MD, chief academic officer, Ochsner Health.
Through his research, Kenny has significantly impacted how scientists understand nicotine addiction, providing insight for the development of new treatment methods. He conducted innovative studies of the neural and biochemical correlates of nicotine addiction, developed therapies based on these insights, and defined the relation of nicotine addiction to the pancreas and diabetes. Additionally, Kenny demonstrated the relevance of glucagon-like peptide-1 (GLP-1) to the regulation of nicotine craving, leading to the development of therapeutic strategies.